Application of prodrugs to inflammatory diseases of the gut

Molecules

Volumn 13, Issue 2, 2008, Pages 452-474

  Oz, Helieh S ^a   Ebersole, Jeffrey L ^a  

^a UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

Author keywords

5 Aminosalicylic acid; Cysteine and glutathione prodrugs; Digestive tract; Drug delivery; Inflammatory bowel disease; Microbiota; Mycophenolate mofetil

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; IMMUNOLOGIC FACTOR; PRODRUG; REACTIVE OXYGEN METABOLITE;

ANIMAL; CHEMISTRY; ENTERITIS; HUMAN; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PRODRUGS; REACTIVE OXYGEN SPECIES;

EID: 40349087243     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13020452     Document Type: Review

References (126)

1. Tursi, A.; Brandimarte, G.; Giorgetti, G.M.; Nasi, G. Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. Eur. J. Gastroenterol. Hepatol. 2003, 15, 69-74.
2. Schwab, M.; Klotz, U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease, Clin. Pharmacokinet. 2001, 40, 723-751.
3. Dressman, J.B.; Vertzoni, M.; Goumas, K.; Reppas, C. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev. 2007, 59, 591-602.
4. Albert, A. Chemical aspects of selective toxicity. Nature 1958, 182, 421-422.
5. Stella, V.J.; Charman, W.N.A.; Naringrekar, V.H. Prodrugs. Do they have advantages in clinical practice? Drugs 1985, 29, 455-473.
6. Bundgaard, H. Design and application of prodrugs. In A Textbook of Drug Design and Development; Krogsgaard-Larsen, P., Bundgaard, H., Eds.; Harwood: Reading, UK, 1991; pp. 113-191.
7. Ettmayer, P.; Amidon, G.L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
8. Han, H.K.; Amidon, G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharm. Sci. 2000, 2, E6.
9. Rubinstein, A. Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 1995, 12, 101-149.
10. Hovgaard, L.; Brondsted, H. Current applications of polysaccharides in colon targeting. Crit. Rev. Ther. Drug Carr. Syst. 1996, 13, 185-223.
11. Fang, L.; Battisti, R.F.; Cheng, H.; Reigan, P.; Xin, Y.; Shen, J; Ross, D.; Chan, K.K.; Martin, J.; Wang, P.G.; Sun, D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-Galactosidase conjugates. J. Med. Chem. 2006, 49, 6290-6297.
12. Curini, M.; Epifano, F.; Genovese, S. Synthesis of a novel prodrug of 3-(4′-geranyloxy-3′-methoxyphenyl)-2-trans-propenoic acid for colon delivery. Bioorg. Med. Chem. Lett. 2005, 15, 5049-5052.
13. Podolskiy, D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347, 417-429.
14. Hutfless, S.M.; Weng, X.; Liu, L.; Allison, J.; Herrinton, L.J. Mortality by Medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007, 133, 1779-1786.
15. Cohen, R.D.; Woseth, D.M.; Thistel, R.A.; Hanauer, S.B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol. 2000, 95, 1263-1276.
16. Li, M.C.; He, S.H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. 2004, 10, 620-625.
17. Neurath, M.F.; Pettersson, S.; Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nature Med. 1996, 2, 998-1004.
18. Neuman, M.G. Immune dysfunction in inflammatory bowel disease. Transl. Res. 2007, 149, 173-186.
19. Kozuch, P.L.; Hanauer, S.B. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol. Clin. North Am. 2006, 35, 757-773.
20. Kozuch, P.L.; Hanauer, S.B. Treatment of inflammatory bowel disease: A review of medical therapy. World J. Gastroenterol. 2008, 4, 354-377.
21. Sartor, R.B. Enteric microflora in IBD: pathogens or commensals? Inflamm. Bowel Dis. 1997, 3, 230- 235.
22. Robertson, D.J; Sandler, R.S. Measles virus and Crohn's disease: a critical appraisal of the current literature. Inflamm. Bowel Dis. 2001, 7, 51- 57.
23. Sartor, RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In Inflammatory Bowel Disease; Kirsner, J.B., Shorter, R.G., Eds.; Williams and Wilkens: Baltimore, 1995; pp. 96-124.
24. Elson, C.O.; Sartor, R.B. Tennyson, G.S.; Riddell, R.H. Insights into the pathogenesis of IBD provided by new rodent models of colitis. Inflam. Bowel Dis. 1995, 1, 64-75.
25. Sadlack, B.; Merz, H.; Schorle, H.; Schimpl, A.; Feller, A.C.; Horak, I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75, 255-261.
26. Sellon, R.K.; Tonkonogy, S.; Schultz, M.; Dieleman, L.A.; Grenther, W.; Balish, E.; Rennick, D.M.; Sartor, R.B. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in IL-10-deficient mice. Infect. Immun. 1998, 66, 5224-5231.
27. MacDermott, R.P.; Stenson, W.F. Inflammatory Bowel Disease. In Immunology and Immunopathology of the liver and gastrointestinal tract; Targan, S.R., Shanahan, F., Eds.; Igaku-Shoin: New York, 1990; pp. 459-486.
28. Gaetke, L.M.; Frederich, R.C.; Oz, H.S.; McClain, C.J. Zinc deficiency induced changes in plasma leptin, metabolic rate, and physical activity in rats. J. Nutr. Biochem. 2002, 13, 237-244.
29. Grave, G. Antioxidant nutrients in inflammatory bowel disease. In Progress in inflammatory bowel disease, Trends in IBD Care; CCFA: New York, 1994; pp. 12-14.
30. Hatoum, O.A.; Binion, D.G.; Gutterman, D.D. Paradox of simultaneous intestinal ischaemia and hyperaemia in inflammatory bowel disease. Eur. J. Clin. Invest. 2005, 35, 599-609.
31. Berg, R.D. The indigenous gastrointestinal microflora. Trends Microbiol. 1996, 4, 430-435.
32. Shanahan, F. Probiotics in inflammatory bowel disease - therapeutic rationale and role. Drug Deliv. Rev. 2004, 56, 809-818.
33. Wang, J.H.; Redmond, H.P.; Watson, R.W.; Bouchei-Hayes, D. Role of lipopolysaccharide and tumor necrosis factor-alpha in induction of hepatocyte necrosis. Am. J. Physiol. 1995, 269, G297-G304.
34. Beutler, B.; Kruys, V. Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. J. Cardiovasc. Pharmacol. 1995, 25 (suppl. 2), S1-S8.
35. Pastor Rojo, O.; López San Román, A.; Albéniz Arbizu, E.; de la Hera Martínez, A.; Ripoll Sevillano, E.; Albillos Martínez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2007, 13, 269-277.
36. Gaetke, L.; Oz, H.S.; Frederich, R.; McClain, C. Anti-TNF-?́ Antibody Normalizes Serum Leptin in IL-2 Deficient Mice. J. Amer. Coll. Nutri. 2003, 22, 415-420.
37. Conner, E.M.; Brand, S.; Davis, J.M.; Laroux, F.S.; Palombella, V.J.; Fuseler, J.W.; Kang, D.Y.; Wolf, R.E.; Grisham, M.B. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J. Pharmacol. Exp. Ther. 1997, 282, 1615-1622.
38. Scheinman, R.I.; Cogswell, P.C.; Lofquist, A.K.; Baldwin, A.S. Role of transcriptional activation of IΚB-α in mediation of immunosuppression by glucocorticoids. Science 1995, 270, 283-286,
39. Auphan, N.; DiDonato, J.A.; Rosette, C.; Helmberg, A.; Karin, M.; Immunosuppression by glucocorticoids: inhibition of NF-ΚB activity through induction of IΚB synthesis. Science, 1995, 270, 286-290.
40. Wahl, C.; Liptay, S.; Adler, G.; Schmid, R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 1998, 101, 1163-1174.
41. Yang, F.; de Villiers, W.J.S. ; McClain, C.J.; Varilek, G.W. Mesalamine (5-ASA) modulates NFkB/ IkB-α activity In Caco-2 cells. Gastroenterology 1997, 112, A1125.
42. Meyer, S.; Kohler, N.G.; Joly, A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation. FEBS Lett. 1997, 413, 354-358.
43. Grisham, M.B.; Granger, D.N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig. Dis. Sci. 1988, 33, 6S-15S.
44. Beckman, K.B.; Ames, B.N. Oxidative decay of DNA. J. Biol. Chem. 1997, 272, 19633-19636.
45. Babbs, C.F. Oxygen radicals in ulcerative colitis. Free Radic. Biol. Med. 1992, 13, 169-181.
46. Suematsu, M.; Suzuki, M.; Kitahora, T.; Miura, S.; Suzuki, K.; Hibi, T.; Watanabe, M.; Nagata, H.; Asakura, H.; Tsuchiya, M. Increased respiratory burst of leukocytes in inflammatory bowel diseases-the analysis of free radical generation by using chemiluminescence probe. J. Clin. Lab. Immunol. 1987, 24, 125-128.
47. Simmonds, N.J.; Allen, R.E.; Stevens, T.R.; Van Someren, R.N.; Blake, D.R.; Rampton, D.S. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992, 103, 186-196.
48. Shiratora, Y.; Aoki, S,, Takada, H.; Kiriyama, H.; Ohto, K.; Hai, K.; Teraoka, H.; Matano, S.; Matsumoto, K.; Kamii, K. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 1989, 44, 163-171.
49. Stein, R.B.; Hanauer, S.B. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000, 23, 429-448.
50. Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPARγ as a new therapeutic target in inflammatory bowel disease. Gut 2006, 55, 1341-1349.
51. Sands, B.E. Therapy of inflammatory bowel disease. Gastroenterology 2000, 118, S68-S82.
52. Kinget, R.; Kalala, W.; Vervoort, L.; Mooter, G.U. Colonic drug targeting. J. Drug. Target. 1998, 6, 129-149.
53. Scheline, R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 1973, 25, 451-523.
54. Hanauer, S.B. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment. Pharmacol. Ther. 2006, Suppl 3, 37-40.
55. Staerk Laursen, L.; Stokholm, M.; Bukhave, K.; Rask-Madsen, J.; Lauritsen, K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990, 31, 1271-1276.
56. Dhaneshwar, S.S.; Gairola, N.; Kandpal, M.; Vadnerkar, G.; Bhatt, L. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid- induced colitis in rats. Bioorg. Med. Chem. 2007, 15, 4903-4909.
57. Bishop, J.; Furman, M.; Thomson, M. Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring. J. Pediatr. Gastroenterol. Nutr. 2007, 45, 50-55.
58. Oosterhuis, B.; Jonkman, J.H. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion, 1989, 44 suppl. 1, 9-17.
59. Topping, D.L.; Clifton, P.M. Short chain fatty acids and human colonic function: roles of resistant starch and non-starch polysaccharides. Physiol. Rev. 2001, 81, 1031-1064.
60. Bergman, E.N. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 1990, 70, 567-590.
61. Brouns, F.; Kettlitz, B.; Arrigoni, E. Resistant starch and "butyrate revolution." Trends Food Sci. Technol. 2002, 13, 251-261.
62. Caderni, G.; Luceri, C.; Lancioni, L.; Tessitore, L.; Dolara, P. Slow-release pellets of sodium butyrate increase apoptosis in the colon of rats treated with azoxymethane, without affecting aberrant crypt foci and colonic proliferation. Nutr. Cancer 1998, 30, 175-181.
63. Scheppach, W. ; Sommer, H. ; Kirchner, T. ; Paganelli, G.M. ; Bartram, P. ; Christl, S. ; Richter, F. ; Dusel, G. ; Kasper, H. Effect of butyrate enema on the colonic mucosa in distal ulcerative colitis. Gasteroentrology 1992, 103, 51-56.
64. Illman, R.J. Topping, D.L.; McIntosh, G.H.; Trimble, R.P.; Storer, G.B.; Taylor, M.N. The hypocholesterolaemic effects of dietary propionate: studies in whole animals and perfused rat liver. Ann. Nutr. Metab. 1988, 32, 97-107.
65. Annison, G.; Illman, R.J. Topping, D.L. Acetylated propionylated or butyrylated starches raise large bowel short-chain fatty acids preferentially when fed to rats. Nutrition 2003, 133, 3523-3528.
66. Bennett, M.J.; Rinaldo, P.; Strauss, A.W. Inborn errors of mitochondrial fatty acid oxidation. Crit. Rev. Clin. Lab. Sci. 2000, 37, 1-44.
67. Rinaldo, P. Fatty acid transport and mitochondrial oxidation disorders. Semin. Liver Dis. 2001, 21, 489-500.
68. Rinaldo, P.; Matern, D.; Bennett, M.J. Fatty acid oxidation disorders. Annu. Rev. Physiol. 2002, 64, 477-502.
69. 0,+. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G1046-G1053.
70. Lipsky, J.J. Mycophenolate mofetil. Lancet 1996, 348, 1357-1359.
71. Gosio, B. Riceche bacteriologiche e chimiche sulle alterazioni del mais. Riv. Igiene. Sanita Pubblica 1896, 7, 825-868.
72. Hupe, D.J.; Azzolina, B.A.; Behrens, N.D. IMP dehydrogenase from the intracellular parasitic protozoan Eimeria Tenella and its inhibition by mycophenolic acid. J. Biol. Chem. 1986, 261, 8363-8369.
73. Oz, H.S.; Hughes, W. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J. Infect. Dis. 1997, 175, 901-904.
74. Oz, H.S.; Hughes, W.T.; Varilek, G. Provocative effects of immunosuppressants rapamycin, tacrolimus and dexamethasone on P. carinii pneumonitis in contrast to anti-PCP effects of the mycophenolate mofetil. Transplant 2001, 72, 1464-1465.
75. Azevedo, L.S.; Castro, M.C.R.; Paula, F.J.; Ianhez, L.E.; David-Neto, E. Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal patients. Rev. Inst. Med. Trop. S. Paulo 2005, 47, 143-145.
76. Zeeh, J.M. ; Zorlu, Riley, N.E; Hoffmann, P. ; Ruwe, M. ; Goebell, H. ; Gerken, G. ; Dignass, A.U. Mycophenolate mofetil reduces tissue damage and inflammation in an experimental model of colitis in rats. Scand. J. Gastroenterol. 2001, 36, 66-70.
77. Neurath, M.F.; Wanitschke, R.; Peters, M.; Krummenauer, F.; Meyer, zum Buschenfelde, K.H.; Schlaak, J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease [comment]. Gut 1999, 44, 625-628.
78. Orth, T.; Peters, M.; Schlaak, J.F.; Krummenauer, F.; Wanitschke, R.; Mayet, W.J.; Galle, P.R.; Neurath, M.F. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am. J. Gastroenterol. 2000, 95, 1201-1207.
79. Florin, T.H.; Roberts, R.K.; Watson, M.R.; Radford-Smith, G.L. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust. N. Z. J. Med. 1998, 28, 344-345.
80. Miehsler, W.; Reinisch, W.; Moser, G.; Gangl, A.; Vogelsang, H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease. Am. J. Gastroenterol. 2001, 96, 782-787.
81. Golconda, M.S.; Valente, J.F.; Bejarano, P.; Gilinsky, N. First MR. Mycophenolate mofetil induced colonic ulceration in renal transplant recipients. Transplant. Proc. 1999, 31, 272-273.
82. Shaw, L.M.; Nowak, I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther. Drug Monit. 1995, 17, 685-689.
83. Loftus, C.G.; Egan, L.J.; Sandborn, W.J. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 2004, 33, 141-169.
84. Breen, D.P.; Marinaki, A.M.; Arenas, M.; Hayes, P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 2005, 11, 826-833.
85. Marín-Jimenez, I.; Pena, A.S. Budesonide for ulcerative colitis. Rev. Esp. Enferm. Dig. 2006, 98, 362-373.
86. Parks, D.A.; Bulkley, G.B.; Granger, D.N. Role of oxygen-derived free radicals in digestive tract diseases. Surgery 1983, 94, 415-422.
87. Tsuchiya.; M. Free radicals in digestive diseases. In Proceedings of the 1st International Symposium on Free Radicals in Digestive Diseases; Excerpta Medica: New York, 1988; p. 244.
88. Baker, S.S.; Campbell, C.L. Enterocyte injury by O2-dependent processes. Gastroenterology 1991, 101, 716-720.
89. Mrtensson, J.; Jain, A.; Meister, A. Glutathione is required for intestinal function. Proc. Nat. Acad. Sci. 1990, 87, 1715-1719.
90. Uhlig, S.; Wendel, A. The physiological consequences of glutathione variations. Life. Sci. 1992, 51, 1083-1094.
91. Mercier, S.; Breuille, D.; Mosoni, L.; Obled, C.; Patureau Mirand, P. Chronic Inflammation Alters Protein Metabolism in Several Organs of Adult Rats. J. Nutr. 2002, 132, 1921-1928.
92. Oz, H.S.; Chen, T.; McClain, C.J.; deVilliers, W. Antioxidants a novel therapy in a murine model of colitis. J. Nutri. Biochem. 2005, 16, 297-304.
93. Dieleman, L.A.; Palmen, M. J.; Akol, H.; Bloemena, E.; Pena, A.S. Meuwissen, S.G.; et al. Chronic experimental colitis induced by dextran sulfate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 1998, 114, 385-391.
94. Oz, H.S.; Chen, T.; de Villiers, W.; McClain, C. Metallothionein overexpression does not protect against inflammatory bowel disease in a DSS murine colitis model. Med. Sci. Monit. 2005, 11, BR69-73.
95. Sido, B. ; Hack, V. ; Hochlehnert, A. ; Lipps, H. ; Herfarth, C. ; Dröge, W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 1998, 42, 485-492.
96. Chen, T.S., Richie, J.P. Jr; Lang, C.A. Life span profiles of glutathione and acetaminophen detoxification. Drug Metab. Disp. 1990, 18, 882-887.
97. Oz, H.S.; McClain, C.; Nagasawa, H.; Ray, M.; Chen. T. Diverse Antioxidants protect Against Acetaminophen Hepatotoxicity. J. Biochem. Mol. Tox. 2004, 18, 361-368.
98. Robinson, M.K.; Rounds, J.D; Hong, R.W.; Jacobs, D.O.; Wilmore, D.W. Glutathione deficiency increases organ dysfunction after hemorrhagic shock. Surgery 1992, 112,140-7, 148-149.
99. Koch, T.R.; Yuan, L.X.; Fink, J.G.; Petro, A.; Opara, E.C. Induction of enlarged intestinal lymphoid aggregates during acute glutathione depletion in a murine model. Dig. Dis. Sci. 2000, 45, 2115-2121.
100. Tian, J.; Washizawa, N.; Gu, L.H.; Levin, M.S.; Wang, L.; Rubin, D.C.; Mwangi, S.; Srinivasan, S.; Gao, Y.; Jones, D.P.; Ziegler, T.R. Stimulation of colonic mucosal growth associated with oxidized redox status in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R1081-R1091.
101. Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)-thiazolidine-4(R) -carboxylic acids. J. Med. Chem. 1987, 30, 1891-1896.
102. Kleinman W.A.; Richie Jr, J.P. Status of glutathione and other thiols and disulfides in human plasma. Biochem. Pharmacol. 2000, 60, 19-29.
103. Baker, D.H.; Czarnecki-Maulden, G.L. Pharmacologic role of cysteine in ameliorating or exacerbating mineral toxicities. J. Nutr. 1987, 117, 1003-1010.
104. Ardite, E. ; Sans, M. ; Panes, J. ; Romero, F. ; Pique, J.M. ; Fernandez-Checa, J. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab. Invest. 2000, 80, 735-744.
105. Kim, H.S.; Berstad, A. Experimental colitis in animal model. Scand. J. Gastroentrol. 1992, 27, 529-537.
106. Iwai, A.; Iwashita, E. Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig. Dis. Sci. 1998, 43, 143S-147S.
107. Nagasawa, H.T.; Goon, D.J.; Muldoon, W.P. Zera, R.T. 2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine, protection of mice against acetaminophen hepatotoxicity. J. Med. Chem. 1984, 27, 591-596.
108. Rathbun, W.B.; Nagasawa, H.T.; Killen; C.E. Prevention of naphthalene-induced cataract and hepatic glutathione loss by the L-cysteine prodrugs, MTCA and PTCA. Exp. Eye Res. 1996, 62, 433-441.
109. Butler, J.D.B.; Spielberg, S.P. Accumulation of cystine from glutathione-cysteine mixed disulfide in cystinotic fibroblasts; blockade by an inhibitor of γ-glutamyl transpeptidase. Life Sci. 1982, 31, 2563-2570.
110. Berkeley, L.I.; Cohen, J.F.; Crankshaw, D.L.; Shirota, F.; Nagasawa, H.T. Hepatoprotection by L-cysteine-glutathione mixed disulfide, a sulfhydryl-modified prodrug of glutathione. J. Biochem. Mol. Toxicol. 2003, 17, 95-97.
111. Eriksson, S.A., Mannervik, B. The reduction of the L-cysteine-glutathione mixed disulfide in rat liver. Involvement of an enzyme catalyzing thiol-disulfide interchange. FEBS Lett. 1970, 7, 26-28.
112. Oz, H.S.; Ray, M.; Chen, T.S.; McClain, C.J. Efficacy of a TGF-β2 Containing Nutritional Support Formula in a Murine Model of IBD. J. Amer. Coll. Nutri. 2004, 23, 220-226.
113. Zhong, J.; Eckhardt, E.R.; Oz, H.S.; Bruemmer, D.; de Villiers, W.J. Osteopontin-deficiency protects mice from dextran sodium sulfate-induced colitis. Inflam. Bowel. Dis. 2006, 12, 1-7.
114. Oz, H.S.; Chen, T.; Nagasawa, H. Comparative Efficacies of Two Cysteine Prodrugs and a Glutathione Delivery Agent in a Colitis Model. Translat. Res. 2007, 150, 122-129.
115. Srinivasan, C.; Williams, W.M.; Ray, M.B.; Chen, T.S. Prevention of acetaminophen-induced liver toxicity by 2(R,S)-n-propylthiazolidine-4(R)- carboxylic acid in mice. Biochem. Pharmacol. 2001, 61, 245-252.
116. Srinivasan, C.; Williams, W.M.; Nagasawa, H.T.; Chen, T.S. Effects of 2(RS)-n-propylthiazolidine-4(R)-carboxylic acid on extrahepatic sulfhydryl levels in mice treated with acetaminophen. Biochem. Pharmacol. 2001, 61, 925-931.
117. Oz, H.S.; Im, H.J.; Chen, T.S.; de Villiers, W.J.; McClain, C.J. Glutathione enhancing agents protect against Steatohepatitis in a model. J. Biochem. Mol. Tox. 2006, 20, 39-47.
118. Holleschau, A.M.; Rathbun, W.B.; Nagasawa, H.T. An HPLC radiotracer method for assessing the ability of L-Cysteine prodrugs to maintain glutathione levels in the cultured rat lens. Curr. Eye Res. 1996, 15, 510.
119. Mato, J.M.; Alvarez, L.; Ortiz, P.; Pajares, M.A. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol. Ther. 1997, 73, 265-280.
120. Lu, S.C. S-Adenosylmethionine. Int. J. Biochem. Cell. Biol. 2000, 32, 391-395.
121. Giulidori, P.; Galli-Kienle, M.; Catto, E.; Stramentinoli, E. Transmethylation, transsulfuration, and aminopropylation reactions of S-adenosyl-L-methionine in vivo. J. Biol. Chem. 1984, 259, 4205-4211.
122. Roediger, W.E.; Babidge, W.; Millard, S. Methionine derivatives diminish sulphide damage to colonocytes - implications for ulcerative colitis. Gut 1996, 39, 77-81.
123. Roediger, W.E.; Babidge, W.J. Thiol methyltransferase activity in inflammatory bowel disease. Gut 2000, 47, 206-210.
124. Moore, J.W.; Babidge, W.J.; Millard, S.H.; Roediger, W.E. Thiolmethyltransferase activity in the human colonic mucosa: implications for ulcerative colitis. J. Gastroenterol. Hepatol. 1997, 12, 678-684.
125. Obayashi, M.; Matsui-Yuasa, I.; Matsumoto, T.; Kitano, A.; Kobayashi, K.; Otani, S. Polyamine metabolism in colonic mucosa from patients with ulcerative colitis. Am. J. Gastroenterol. 1992, 87, 736-740.
126. Oz, H.S.; Chen, T.; Neuman, M. Methionine deficiency and liver injury in a dietary NASH model. Dig. Dis. Sci. 2007, DOI: 10.1007/s10620-007-9900-7.